The document provides an overview of the pharmaceutical industry in India. It discusses that India has emerged as a major player in the global pharma industry, ranking 3rd in volume and 10th in value. The country exports generic drugs and has become an important destination for contract research and manufacturing. The industry is expected to grow significantly, with sales projected to reach $74 billion by 2020. Key strengths that will support this growth include a large talent pool with skills in areas like R&D, manufacturing according to international standards at low costs, and a favorable regulatory environment. However, increased competition and a stringent regulatory environment also pose threats.

2. sUB
PHARMA
INDUSTRY

3. Agenda:-
Introduction
Major player
Indian scenario
Global scenario
SWOT
Future Prospect

4. Introduction
•In 1930,in culcutta the first pharma company called Bengal
Chemicals & pharmaceuticals world,which still is today as one of 5
Govt.-owned drug manufacturers was started.
•The History of Indian pharma market in 1970 was almost non-existent.
Today India has gained immense importance & carved a niche for itself
,In the pharma domain.Infact,it has emerged as big mart for the
pharma Industry.
•Formulations,bulk drugs,generics,novel drug delivery systems,new
chemical entities,or biotechnology etc.Indian co.dominating in market
place which was traditionally manned by MNC.

7. Indian Scenario
•India has been ranked third in terms of volume & tenth in terms of
value,globally.
•The country is the largest exporter globally of generic formulations in volume.
•India is now among the top 5 pharmaceuticals emerging market,pharma
industry contributed 1.71% of GDP.
•The growing size of the indian geriatric population will be a key factor in
influencing the growth of the chronic segment.
•The varied function such as contract research & manufacturing,clinical
research,R & D pertaining to vaccines are the strengths of the pharma industry
in india.Multinational pharma coperations outsource these activities and help
the growth of the sectors.The indian pharma industy has a bright future.

8. Global Scenario
•The Indian pharma industry is one of the fastest emerging
international center for contract Research & manufacturing
services.
•The main factor of the growth of the CRAMS is due to the
international standard quality and Low cost.
•US constitutes 27% of India’s pharma exports,followed by
Europe 19 percent,middle east 7 Percent,Latin america 6
percent & other five percent.
•Export of pharma in 2004 was rs.17,000cr.In the last nine
years,it reported a strong growth & in 2014,Exports stood at
rs.63,500cr.

9. Contd….
•Around 50 more new manufacturing units are to be set up in
accordance to the UK MHRA Standards.
•With these all development India is posed to become the
biggest producers of drugs in the World.
•Indians already has the biggest number of US FDA
standardize manufacturing units outside the territory of US.

11. Future outlook
• US$ 74 billion in sales by 2020.
• Annual growth rate of 14-17 Percent over 12-16.
• Top ten pharma based markets In the world in the next 10 yrs.
• Rise in the sales of the patent drugs.
•(Medical infrastructure),growth of pharma industry
•Major FDI encouraging sector in India.

13. History
•Pfizer is a pharmaceutical company Founded in 1849
by two cousins named Charles Pfizer and Charles
Erhart.
•Company creates products to prevent and treat
diseases and improve the health of people around the
globe.
•Determined to constantly meet the expectations and
demand of stakeholder and society as a whole

14. Company overview
Three Business segment
•Pharmaceuticals
•Animal health
•Corporate/other
•Pfizer Inc. is the largest research based pharmaceuticals company
through the:-
•Discovery/Development/manufacturing & marketing of
prescription medicines for Humans & Animals.

15. Strength
1. One of the largest pharmaceutical company in the world and spread over more
than 50 countries.
2. Excellent research and development (R&D) creating innovative and
breakthrough products
3. Mergers and acquisitions with big pharma brands increasing brand reputation
4. Has over 100,000 employees as a part of the organization
5. Strong brand name and recall globally
Weakness
1Tough competition from other major pharma brands means limited scope for
market share growth
2.Negative brand image due to involvement in largest healthcare fraud of
marketing its drug illegally
Opportunity
1.Strategic agreements with other pharmaceutical companies
and organizations to boost its research.
2. Increasing awareness about healthcare needs
3. Global penetration through mergers and acquisitions
4. Increasing demand for quality healthcare solutions
Threats
1.Risk of unsuccessful new Products
2.Regulatory environment is becoming more & more stringent
3.Economic slowdown in European markets
SWOT

16. Ian C. READ(CEO)
Frank D’Amelio(CFO)
Rady Johnson(Executive V.P)
Geno Germano(Group P.)
Freda c.lewis(CMO)
Key Executives(co. mgt.)
Mr. Jeffrey
B. Kindler
Mr. Frank A.
D'Amelio
Mr. Ian C.
Read
Dr. Martin
Mackay
Dr. Freda C.
Lewis-Hall
M.D., FAPA

17. Major Products I
Lipitor
•Treatment for elevated LDL cholestrol level
•best-selling pharmaceutical product in the world

18. Major Products II
Norvasc
•World’s most-prescribed branded antihypertensive therapy
•4th best-selling drug in the world

19. Major Products III
Zoloft
•Most- prescribed anti-depressant in US
•10 best selling drug in the world

20. Other Products
Viagra
Treats erectile dysfunction (ED)
Cannot exceed the maximum dose of 25mg in 48 hours
Benadryl
•Treats allergy symptoms
•Treating adult allergic reaction 25-50 mg every 4-6
hours
Cefazolin
•To reduce the development of drug- resistant bacteria
•Moderate to sever infection 500 mg- 1 gram every 6-8
hours

21. Pfizer’s competitors
•Merck & Co. Inc.
•Novartis AG
•Bayer Aktienges ADS

23. Skills required:-
•Quality assurance
•R &D
•Bioinformatics
•Engineering
•Consumer insight
•Clinical research
•Sales & Marketing

24. HRM Role
•To partner the sales function & regional office in providing
proactive,continuous,Reliable & responsive end to end support.
•To be responsible for implementing HR processes of Recruitment,training,&
development .
•Hr responsible for overall functions of plant.
•Assisting plant head to achieve target & company objective.
•Compliance with social welfare of the employee & labor laws.

25. HRM Challenges:-
•Challenge of supplying different skill sets as per the requirement of the
industry
•Same time, continuously raising the employee performance bar as per the
business Need.
•Attracting & retaining R& D professionals is an important task.
•Debate between temporary appointment versus permanent appointment.

26. Thanking
you